No Carolina / NY / Florida
Ph: 561.316.3330

NIOX® Group Celebrates 25 Years of Innovation in FeNO Testing for Asthma

Summation

  • NIOX® technology, developed by the visionary scientists who discovered the value of FeNO (fractional exhaled nitric oxide) testing in asthma, has played a pivotal role in helping to transform the way asthma can be diagnosed and managed.
  • With a continued focus on delivering market-leading products and unparalleled support to healthcare professionals, NIOX® aims to further solidify its position as a global leader in FeNO testing.
  • As the company looks to the future, it continues to invest in research and development to further enhance NIOX® technology.

NIOX® Group (NIOX®) proudly announces the celebration of the 25th anniversary of its cutting-edge asthma diagnosis and management technology. Since its foundation, the company has worked to help improve asthma care with its ground-breaking FeNO testing devices. With almost 50 million tests performed worldwide, NIOX® continues to lead the development of FeNO for patient care.

NIOX® technology, developed by the visionary scientists who discovered the value of FeNO (fractional exhaled nitric oxide) testing in asthma, has played a pivotal role in helping to transform the way asthma can be diagnosed and managed.1-4 FeNO testing has become an important tool for healthcare professionals in assessing airway inflammation and guiding treatment decisions.4-7 The milestone achievement of nearly 50 million FeNO tests performed using NIOX® technology is testament to its widespread adoption and impact on patient health.

In recognition of its commitment to innovation, NIOX® has received prestigious accolades. In 2021, the company was honoured with the award for Most Innovative Asthma Management Technology, highlighting its pioneering contributions to the field. In 2022, NIOX® was named Best FeNO Testing Provider and acknowledged as Leaders in FeNO Testing Technology Development later that same year. These awards not only reflect the dedication of the entire team at NIOX® but also validate the confidence placed in the company by healthcare professionals worldwide.

NIOX® Executive Chairman, Ian Johnson, said: “On this momentous occasion, we would like to express our sincere gratitude to our colleagues and to our customers for their continued support. The success of the past 25 years would not have been possible without the dedication and hard work of the talented individuals who have been part of the NIOX® family. Their commitment to advancing asthma care has been instrumental in shaping the company’s success. Thank you all.”

NIOX® remains committed to driving innovation in asthma management and improving the lives of patients. As the company looks to the future, it continues to invest in research and development to further enhance NIOX® technology. With a continued focus on delivering market-leading products and unparalleled support to healthcare professionals, NIOX® aims to further solidify its position as a global leader in FeNO testing.

Watch the fascinating story of FeNO testing in a new short film:

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img
spot_img
spot_img

Stay Connected

spot_img
spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy